Altazinc

Quick links to important sections

Altazinc

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Altazinc

Quick Facts

Property Description
Active ingredient Zinc Sulfate (ZnSO₄)
Form Oral solution, tablet, capsule
Pharmacological class Micronutrient supplement, essential trace element
Common purpose Correction or prevention of zinc deficiency
Origin Naturally occurring mineral, formulated as an inorganic salt

What is Altazinc? Definition and Pharmacological Classification

Altazinc is a pharmaceutical preparation utilizing Zinc Sulfate (ZnSO₄) as its active ingredient to serve as a micronutrient supplement and an essential trace element. It is classified within the general drug class of minerals and electrolytes. This is a single-ingredient product designed to reliably supply the body with the indispensable mineral zinc. Oral zinc supplementation is a recognized strategy for maintaining health, as the drug’s primary role is to provide a fundamental nutritional requirement.

Composition, Forms, and Origin of the Active Ingredient

The active component, Zinc Sulfate, is an inorganic salt derived from the naturally occurring mineral zinc, which is then synthetically processed into a stable form. Altazinc is intended for oral administration and is typically presented in multiple dosage forms, including the liquid oral solution, which is often preferred for pediatric patients, and solid forms such as tablets or capsules. The use of the sulfate salt is recognized for its relatively consistent absorption profile in the gastrointestinal tract, supporting its use in cases of documented zinc deficiency.

General Purpose and Biological Importance of Altazinc

The core function of Altazinc is to address or prevent a state of zinc deficiency, thereby supporting wide-ranging physiological processes. The mineral is essential because it acts as a critical cofactor for numerous enzymes involved in metabolic reactions, including those necessary for healthy protein and DNA synthesis. By sustaining adequate zinc levels, the medicine contributes fundamentally to the maintenance of healthy immune function, a benefit supported by clinical research.

Regulatory References

  1. Zinc Sulfate
  2. micronutrient supplement
  3. essential trace element
  4. MedlinePlus
  5. oral
  6. dosage forms
  7. oral solution
  8. zinc deficiency
  9. cofactor for numerous enzymes
  10. protein and DNA synthesis
  11. immune function

What side effects are possible with Altazinc?

Possible Side Effects and Safety Information

The safety profile of Altazinc (Zinc Sulfate) is primarily characterized by effects involving the Gastrointestinal System. Regulatory documents classify adverse reactions based on their frequency of occurrence, with specific safety patterns noted for treatment duration and certain patient groups.


Frequency-Classified Adverse Reactions

The most commonly reported effects are concentrated in the digestive tract. Clinical data for oral zinc sulfate, particularly in children, specifies the following frequencies:

Classification Common Adverse Reactions
Very Common Vomiting
Common Nausea, upset stomach, regurgitation
Frequency Unknown Abdominal pain, dyspepsia

These gastrointestinal events often occur shortly after the first dose and may not be recurrent. Systemic issues are less frequent but include high-level risks documented in official labeling.


Serious Safety Considerations

The official safety information highlights two main areas of serious concern. The first involves Hypersensitivity Reactions, which are documented as a potential serious adverse event and may present as signs of a severe allergic response, such as difficulty breathing or swelling. The second major consideration relates to Dose and Exposure.

Prolonged, High-Dose Exposure to zinc sulfate can interfere with the body's mineral balance, potentially leading to Copper Deficiency (hypocupremia), a documented risk in the regulatory profile. Additionally, the label specifies that massive overdose can lead to severe gastrointestinal corrosion and acute kidney injury.


Population-Specific Safety Notes

Official labeling addresses specific populations. For pediatrics, vomiting is classified as Very Common. For patients with Phenylketonuria (PKU), specific oral formulations may contain aspartame. Use during pregnancy and lactation is generally considered safe at therapeutic doses, though zinc is known to appear in human milk.

Overdose and Emergency Response

Altazinc Overdose and When to Seek Help

Acute overdose with Altazinc (Zinc Sulfate) is documented by regulatory bodies to present primarily with severe gastrointestinal distress. Officially listed manifestations include nausea, vomiting, diarrhea, abdominal pain, fever, metallic taste, and lethargy.

Severe Outcomes and Required Action

Regulatory information warns of the potential for severe corrosive injury following high-dose ingestion. This local damage can lead to inflammation, ulceration, and potential perforation of the gastrointestinal tract. More serious systemic outcomes documented in official sources include acute renal tubular necrosis and sudden hypotension. Given the potential for life-threatening complications, immediate medical help must be sought following any suspected overdose.

Clinical Feature Official Statement
Urgent Action Consult a doctor; seek immediate medical attention.
Initial Step Demulcents such as milk or water should be given immediately.
Management Constraint Gastric lavage and emesis must be avoided due to the risk of exacerbating corrosive damage.

Overdose management is primarily supportive. Official labeling indicates that specific monitoring of zinc blood levels and comprehensive observation may be required. The product information also notes that patients with renal failure are at an increased risk of zinc accumulation following exposure to high amounts, requiring special consideration.

Therapeutic Uses of Altazinc

What Altazinc Treats: Main Uses and Benefits

Altazinc (Zinc Sulfate) provides supportive therapeutic benefit by addressing zinc inadequacy and is commonly used across domains where additional symptomatic support is needed. It helps manage or address conditions marked by increased physiological stress, such as chronic gastrointestinal disorders that impair nutrient absorption.

Management of Deficiency and Developmental Support

The medication is relevant for a broad scope of therapeutic needs, including managing states of zinc inadequacy; assisting with symptoms related to delayed tissue repair; and supporting children with slowed growth and development; and acting as an adjunct in treating acute or persistent watery diarrhea. This mineral is relevant for symptom patterns associated with impaired physical growth, delayed healing, and low immune response.

Supportive Care for Chronic Symptom Patterns

The patient-oriented benefit is the support it offers during systemic imbalance, which generally assists with maintaining functional stability when essential functions become compromised. Altazinc may be part of symptomatic management to help manage symptoms associated with the decline in visual function in certain age-related eye conditions, and it assists with addressing symptom patterns associated with a low immune response.

Quick Fact: Relief for Deficiency Symptoms
Helps address Symptoms related to loss of normal taste perception (hypogeusia) and chronic skin lesions.
Supports Symptom management related to physical growth and low immune response.

Eligibility and Restrictions for Use

Altazinc (Zinc Sulfate) eligibility is determined by official regulatory classifications that specify who is permitted to use the medicine and who is prohibited. Use is established for adult and pediatric patients requiring zinc supplementation via parenteral nutrition. The oral form is indicated for infants and children up to 5 years for conditions like diarrhea, with specific dosing for children less than six months of age.


Contraindicated and Restricted Populations

Contraindicated Populations (Must Not Use) Restricted/Conditional Use
Known hypersensitivity to zinc or any formulation component. Renal Impairment: Use with caution due to the risk of zinc accumulation or aluminum toxicity with prolonged parenteral administration.
Copper deficiency (for some oral forms). Preterm Infants: High-risk group for aluminum toxicity if kidney function is immature (parenteral use).
Conditions like Phenylketonuria if the formulation contains excipients such as aspartame. Geriatric Patients: Dose selection requires individualization based on clinical status.

Regarding pregnancy and lactation, regulatory safety documentation varies by product. For the injectable form, administration of the recommended dose is not expected to cause major adverse outcomes. However, the safety of some oral formulations in both pregnancy and lactation is often stated as not established.

What should I know about interactions with other medicines?

Altazinc Interactions with other medicines and products

The interaction profile of Altazinc (Zinc Sulfate) is governed by its nature as a polyvalent cation, resulting in pharmacokinetic interference, primarily the reduction of absorption, when co-administered with specific medicinal products or foods. This often leads to a clinically significant reduction in the systemic exposure (AUC/Cmax) of either Altazinc or the interacting substance.


Interaction Scope

Property Details
Medicinal product categories with documented interactions Tetracycline antibiotics, Quinolone antibacterials, Chelating agents (e.g., Penicillamine, Trientine), Oral iron supplements.
Specific interacting medicines (if explicitly listed) Ciprofloxacin, Levofloxacin, Cephalexin, Ceftibuten, Copper.
Mechanistic basis of interactions Reduction of absorption due to the formation of insoluble complexes in the gastrointestinal tract.
Timing-based interaction rules Mandatory separation of at least 3 hours for Tetracyclines and Quinolones. Mandatory separation of at least 2 hours before or 2 hours after for Penicillamine and Trientine.
Population-specific interaction notes Risk of trace metal accumulation in patients with renal dysfunction due to altered clearance.
Interaction-related restrictions Consumption with foods high in fiber, calcium, or phosphorus (e.g., dairy products) is documented to reduce zinc absorption.

Official Interaction Statements

  • Co-administration with Tetracyclines or Quinolone Antibacterials is officially documented to reduce the absorption and efficacy of the antibiotic.
  • Altazinc and agents like Penicillamine mutually inhibit each other's absorption, necessitating a minimum time separation for administration.
  • Zinc is documented to functionally antagonize the intestinal absorption of Copper.

The official regulatory documents define the product’s interaction structure primarily as an absorption-reduction profile requiring precise time-separated administration to maintain therapeutic plasma levels of co-administered drugs. This constraint also extends to specific food components that are documented to reduce Altazinc exposure.

Mechanism of Action

How Altazinc Works: Mechanisms of Action

Enzyme Co-factor and Protein Stabilizer

Altazinc (zinc acetate) delivers essential zinc ions (Zn^2+), which act within domains involving enzyme-mediated signaling and structural integrity. Zinc is a required co-factor for over 300 enzymes, affecting systems where cellular metabolism and protein synthesis are critical. This results in predictable physiological adjustments, influencing cellular processes, including DNA synthesis and cellular proliferation.

Antioxidant and Anti-inflammatory Modulation

The drug engages mechanisms that modulate dysregulated processes by supporting the antioxidant defense system. Zinc ions induce the synthesis of metallothioneins and act as a co-factor for the antioxidant enzyme superoxide dismutase (SOD). This mechanistic cascade helps to scavenge reactive oxygen species (ROS) and stabilize cell membranes, which contributes to modulating mechanisms that control the rate of certain physiological responses by engaging pathways that contribute to the management of cellular reactive oxygen species.

Regulation of Intestinal Copper Absorption

Altazinc modifies early molecular steps that shape systemic physiological outcomes, particularly in the gastrointestinal system. It acts within domains that influence feedback regulation within pathways by stimulating the production of metallothionein in intestinal cells. This protein then binds tightly to copper, thereby reducing the rate of copper translocation across the intestinal epithelium, leading to an influence on the homeostatic mechanism for copper concentration.

Dosage and Administration Information

How to Use Altazinc

Altazinc (Zinc Sulfate) is administered through two principal routes: the oral route (using tablets, capsules, or solutions) for deficiency management, and the intravenous (IV) route exclusively as an additive to total parenteral nutrition (TPN) solutions. All official dosing is standardized and calculated based on the content of elemental zinc, ensuring uniformity across various formulations and strengths.


Administration Scope and Dosing

The administration frequency for IV use and short-course oral regimens is generally once daily. For example, specific oral dosing for children is established at 20 mg of elemental zinc per day for those six months and older, with a lower dose of 10 mg per day for infants under six months.

Oral preparations may be taken with food as a general principle to help mitigate potential gastrointestinal discomfort. IV formulations are strictly intended to be prepared and used only as an admixture in the final PN solution; direct, undiluted injection is not an approved method.


Course Duration and Procedural Rules

The duration of use is scenario-dependent: acute scenarios, such as the adjunct treatment for diarrhea, require a defined course typically lasting 10 to 14 days. For chronic deficiency management or continuous TPN, use is sustained to maintain required plasma levels. Practical procedural rules include the instruction to re-administer a dose if a child vomits within 30 minutes of oral intake, and the requirement to infuse high-concentration TPN solutions via a central venous catheter.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Altazinc

Evidence for Use in Acute Diarrhea in Children

Altazinc was studied for its role as an adjunctive measure in studies addressing acute diarrhea, conditions associated with acute or disruptive episodes, in children. The evidence base includes a large volume of Randomized Controlled Trials (RCTs) and multiple Systematic Reviews and Meta-analyses that have examined this area. Researchers monitored several key outcomes describing episodic or acute changes, such as the number of days the diarrhea lasted and the duration of hospitalization.

The findings from numerous studies reported a pattern where measurements of the diarrheal episode duration were recorded during the study period compared to control groups. Evidence contributes to understanding the evolution of symptoms and the outcomes related to physical discomfort in this specific context.

What remains uncertain is how consistently these results apply across all settings. The evidence quality varies, and significant variability was observed in some studies due to differences in the patient populations and the exact formulations of zinc used. Research provides context but does not offer individual predictions across all geographical and nutritional backgrounds.

Evidence for Support in Skin and Mucosal Conditions

Research was evaluated in specific settings where the body shows outcomes linked to inflammatory or irritative states on the skin and mucosal surfaces. Clinical Trials and Systematic Reviews explored Altazinc's use for recurring oral ulcers and certain types of viral warts. These studies examined measurements of lesion size, pain intensity (a patient-reported outcome describing perceived discomfort), time to outcome, and the frequency of recurrence.

For recurring oral ulcers, some studies described patterns where the clinical presentation of lesions was monitored in some studies. For viral warts, research described findings related to the rate of change over defined time intervals.

Long-term outcomes are not well characterized for these conditions; follow-up durations were limited to the acute or short-term treatment phase, making it difficult to assess the durability of the findings or long-term recurrence patterns. Furthermore, findings were mixed across various studies on certain lesion types, meaning the certainty remains low for some of these applications.

Key Studies & References

  1. Oral zinc for treating diarrhoea in children (Cochrane Review)
  2. Zinc Sulfate Injection, USP - FDA DailyMed Label

Frequently Asked Questions (FAQ)

Common questions about Altazinc (FAQ)


Q: Is Altazinc the same as zinc supplements I can buy over the counter?

Altazinc is a pharmaceutical preparation that delivers zinc sulfate, which is the same active ingredient found in many common over-the-counter (OTC) supplements. Regulatory documents confirm that generic and brand-name products are expected to share the same active ingredient, strength, and route of administration.

Differences typically relate to the specific inactive ingredients or the concentration needed for certain regulated medical uses.


Q: Can Altazinc affect the results of blood tests?

Official labeling advises monitoring of laboratory parameters, such as liver and kidney function and electrolyte status, during Altazinc treatment. This monitoring is typically advised because zinc is an essential mineral involved in wide-ranging physiological processes.

Monitoring helps determine whether the patient’s overall mineral and organ function remains within expected limits while using the medicine.


Q: What are the most common reasons someone might stop taking Altazinc?

The reasons for discontinuation are outlined in the official product information and depend on the patient's situation. For acute use, treatment typically stops once the short, defined course (e.g., 10 to 14 days) is complete.

Other reasons include the appearance of common but persistent side effects, such as stomach upset, or serious adverse reactions like hypersensitivity or, in the case of prolonged use, signs of copper deficiency.


Q: What is the risk of having a serious interaction with other prescription drugs while on Altazinc?

Regulatory documents describe a clinically significant interaction where Altazinc is documented to potentially reduce the absorption and effectiveness of certain antibiotics, specifically tetracycline and quinolone types.

To manage this, official guidance describes that a mandatory time separation is necessary when taking these medicines. The official instructions specify the required delay between taking Altazinc and these interacting medicines.


Q: Is it safe to drive or operate machinery after taking Altazinc?

The official product information states that effects on a person’s ability to drive and use machinery have not been documented. Altazinc is generally not associated with central nervous system side effects that would typically impair these activities.


Q: Can I take vitamins or other supplements while using Altazinc?

Altazinc is known to interact with certain other supplements, which can interfere with the absorption of either medicine. Official documents note reduced absorption when taken with oral iron supplements and copper.

Some research indicates that folic acid may also decrease its absorption. Time-separated administration is often described in regulatory documents as necessary when taking supplements known to interact.


Q: What is the difference between Altazinc and generic zinc sulfate?

Generic zinc sulfate and the brand Altazinc share the exact same active ingredient. Generic versions are stipulated by regulatory agencies to contain the same active ingredient, strength, dosage form, and route of administration.

Generic versions are also required to demonstrate equivalence and work in the same way as the brand-name product. Differences are usually limited to non-active ingredients, such as colors or binding agents.


Q: What kind of research has been done on Altazinc for long-term use?

Long-term outcomes are not well characterized for some secondary uses of Altazinc. However, for its primary use (chronic deficiency), use may be sustained over time.

Furthermore, the label documents a risk of prolonged use or high-dose exposure interfering with the body’s mineral balance, potentially leading to a copper deficiency.


Q: Why do some people confuse Altazinc with antibiotics?

Altazinc is classified as an essential mineral supplement, not an antibiotic. However, there is a strong link due to its clinically significant interaction with certain classes of antibiotics.

Because Altazinc is documented to reduce the absorption and therefore potential effectiveness of these antibacterial medicines, the co-administration instructions are often very strict, which may lead to confusion about its classification.


Q: Is the absorption of Altazinc affected by stomach acid reducers?

Official information indicates that the absorption of zinc sulfate may be reduced by medicines that inhibit or lower the secretion of gastric acid in the stomach. This reduction in acidity can affect how the zinc is absorbed into the body.

Official product information emphasizes the importance of time-separated administration or discussion of all medications with a health professional.


Q: Are there specific patient education resources available for Altazinc from regulatory agencies?

Yes, regulatory agencies like the U.S. FDA publish official patient-facing information for medicines. These resources are designed to be accessible and provide factual details about the drug’s use and safety.

Examples include Patient Package Inserts or Medication Guides, which complement the information provided by healthcare professionals.


Q: What is meant by the 'safety classification' of Altazinc in official documents?

Safety classifications are how regulatory bodies standardize information about potential risks. They are based on two main factors: the frequency of adverse reactions and specific risk categories for populations.

Adverse reactions are ranked by how often they occur (e.g., Very Common, Common). Specific populations (e.g., renal impairment, hypersensitivity) are placed into categories like 'Contraindicated' or 'Restricted Use'.


Q: Are there alternative names or spellings for Altazinc?

The active ingredient in Altazinc is known by its generic chemical name, zinc sulfate. Alternative brand names for oral zinc sulfate preparations include Orazinc, Mar-Zinc, and Verazinc.

Official guidance emphasizes the need to confirm the active ingredient and strength when reviewing medication information.


Q: Why are the instructions about use conditions so specific in the official documents?

The instructions related to use are highly specific to support the intended efficacy of the medicine and to manage specific, known safety risks. The details ensure the correct amount of elemental zinc is delivered.

This specificity also helps prevent serious issues, such as mandating separation from other drugs to maintain efficacy, or specifying central line use for high concentrations to prevent vein damage.

How should Altazinc be stored and disposed of?

The storage and disposal of Altazinc (Zinc Sulfate) must align with official regulatory requirements to ensure product stability and safety.

Storage Conditions

The medication must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). Storage conditions must protect the product from moisture and light, and it is explicitly stated that the product must not be frozen. The medicine must be kept in its original container, tightly closed, and stored out of the sight and reach of children.

Disposal Instructions

Official guidelines state that unused or expired Altazinc must not be flushed down the toilet or poured down a drain, and should not be discarded in general household trash. Consumers are directed to consult a pharmacist or healthcare provider for information on approved local medicine take-back programs or other established pharmaceutical waste disposal pathways. The product must not be released into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Altazinc found in:

A-Z Index: